Rapid Micro Biosystems (NASDAQ:RPID) COO John Addington Wilson Sells 9,603 Shares

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) COO John Addington Wilson sold 9,603 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total transaction of $41,484.96. Following the sale, the chief operating officer owned 316,762 shares of the company’s stock, valued at approximately $1,368,411.84. This represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Rapid Micro Biosystems Stock Down 17.7%

Rapid Micro Biosystems stock traded down $0.61 during trading on Friday, reaching $2.82. 715,869 shares of the company’s stock were exchanged, compared to its average volume of 273,783. Rapid Micro Biosystems, Inc. has a 52-week low of $1.86 and a 52-week high of $4.94. The firm has a market cap of $124.77 million, a price-to-earnings ratio of -2.79 and a beta of 1.38. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 4.23. The company’s 50-day moving average is $3.98 and its two-hundred day moving average is $3.54.

Rapid Micro Biosystems (NASDAQ:RPID) last posted its earnings results on Thursday, March 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). The firm had revenue of $11.28 million for the quarter, compared to analyst estimates of $10.93 million. Rapid Micro Biosystems had a negative return on equity of 73.90% and a negative net margin of 145.11%. On average, analysts predict that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current year.

Institutional Trading of Rapid Micro Biosystems

Several institutional investors have recently modified their holdings of the company. Hudson Bay Capital Management LP bought a new position in Rapid Micro Biosystems during the third quarter valued at approximately $38,000. Fifth Lane Capital LP acquired a new stake in shares of Rapid Micro Biosystems in the fourth quarter worth about $51,000. American Century Companies Inc. grew its holdings in Rapid Micro Biosystems by 46.1% during the second quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock valued at $58,000 after purchasing an additional 5,341 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Rapid Micro Biosystems in the fourth quarter worth $71,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Rapid Micro Biosystems during the 4th quarter worth $72,000. Institutional investors and hedge funds own 52.60% of the company’s stock.

Trending Headlines about Rapid Micro Biosystems

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: Recorded revenue growth and raised outlook: RPID reported record Q4 ($11.3M) and full‑year 2025 ($33.6M) revenue with management providing 2026 revenue guidance of $37.0M–$41.0M and expected system placements, signaling continued commercial traction and scale potential. GlobeNewswire: Record Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Large customer orders: RPID announced follow‑on multi‑system orders (Samsung Biologics) and expanded deployments (Amgen), reinforcing demand from big pharma/CDMO customers and validating the Growth Direct platform in large manufacturing networks. GlobeNewswire: Follow-on Multi‑System Order from Samsung Biologics
• Positive Sentiment: Analyst/coverage note highlights adoption: Independent analysis points to big‑pharma adoption as a key growth driver, which supports upside from recurring placements, service and consumables revenue over time. Seeking Alpha: Big Pharma Adoption Driving Growth
• Neutral Sentiment: Guidance sits near consensus but leaves execution risk: 2026 revenue range is centered near analyst expectations (~$39M midpoint) but the wide range and modest gross margin guidance (~20%) leave outcomes dependent on system placements and margin expansion. Yahoo Finance: Q4 2025 Earnings Report Preview
• Neutral Sentiment: Earnings call highlighted growth vs. pressure trade‑offs: Management framed the quarter as progress on commercial adoption but noted margin and scaling pressures—mixed messaging that can moderate near‑term enthusiasm. TipRanks: Earnings Call Balances Growth, Pressure
• Negative Sentiment: EPS missed despite revenue beat: Q4 EPS came in at ($0.28) vs. consensus ($0.23) miss, and the company remains unprofitable with negative margins—an ongoing profitability concern for investors. MarketBeat: Q4 2025 Earnings and Call
• Negative Sentiment: Recent insider selling by CEO, CFO and COO: Multiple disclosed Form 4 sales by senior executives (March filings) may amplify selling pressure or raise investor concerns about insider conviction. SEC Form 4: CEO Insider Sale

Wall Street Analyst Weigh In

Several equities analysts have recently commented on RPID shares. Wall Street Zen raised Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.00.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.